Inclusion Criteria:

1. The subject fully understands the purpose, nature, method and possible adverse
reactions of the test, voluntarily becomes a participant, and signs an informed
consent form (ICF) before the start of any procedure;

2. Healthy adult males or females aged 18-45 years (including the threshold) at the
time of signing the ICF;

3. At the time of signing the ICF and on the day of hospitalization, the body mass
index (BMI) is 19-24 kg/m2 (including the threshold), and the weight is not less
than 45 kg for women and not less than 50 kg for men;

4. Good health with normal or abnormal results of history, vital signs, physical
examination, 12-lead ECG, laboratory tests (blood routine, blood glucose, blood
biochemistry, urine routine and coagulation tests) and hemodialysis during the
screening period (NCS);

5. Fertile Women (WOCBP) subjects must consent to the use of one or more effective
contraceptive methods from the screening period to 30 days after the last dose;

6. Fertile male subjects must consent to the use of one or more effective contraceptive
methods within 30 days from the first dose to the last dose;

7. The subject is able to communicate well with the investigator (or designee) and
understands and complies with the requirements of the study.

Exclusion Criteria:

1. Patients who have difficulty in venous blood collection or have a history of needle
fainting or blood fainting;

2. Pregnant or lactating;

3. Allergic constitution or allergic to any ingredient in STI-1558 capsule preparation;

4. Within 1 month prior to screening or within 5 half-lives of the drug (subject to
older age) and those who have been enrolled in other clinical trials (including but
not limited to investigational drugs, vaccines, biologics, devices, blood products,
etc.);

5. Have a history of gastrointestinal (such as duodenal ulcer, gastrointestinal
bleeding), liver or kidney related, or other medical history that the investigator
(or his designee) determines may affect the absorption, distribution, metabolism,
and excretion of oral drugs;

6. Have any clinical history of serious diseases (including but not limited to
respiratory system, circulatory system, digestive system, blood system, endocrine
system, immune system, skin and mucosal system, psychiatric nervous system, ent
department and other related diseases);

7. Those who underwent major surgery within 3 months prior to screening, or did not
fully recover from surgery, or planned to have surgery during the study period;

8. Within 14 days prior to screening and screening of patients with a history of fever;

9. QT interval prolongation: QTcF > 450 msec (male); QTcF > 470 msec (female);

10. Those who were vaccinated within 14 days prior to screening and those who were
screened until check-in or planned to be vaccinated during the study period;

11. Within 7 days before screening and screening of patients who have used BCRP
substrate drugs;

12. Those who have used CYP3A4 inhibitor, strong inducer, or CYP1A2 inhibitor within 7
days prior to screening and those who have been screened;

13. Within 14 days prior to screening or within 5 half-lives of the drug (whichever is
older), and to those who have been admitted to use any other prescription,
over-the-counter or Chinese herbal medicine (other than contraceptive drugs or
topical drugs assessed by the investigator to be applicable);

14. Had a history of drug abuse within 2 years prior to screening, or tested positive
for drug abuse upon admission (D-1);

15. Patients with a history of blood donation or blood loss (excluding female menstrual
blood loss) exceeding 400 mL within 3 months before screening;

16. Those who consumed more than 14 units of alcohol per week in the 3 months prior to
screening (1 unit of alcohol =360 mL beer or 45 mL spirits with 40% alcohol or 150
mL wine), or had consumed alcoholic products within 48 hours prior to the first
dose, or were unable to abstinent during the study period, or tested positive for
alcohol breath test at admission (D-1);

17. Smokers who smoked more than 5 cigarettes per day in the 3 months before screening,
or who could not guarantee no smoking during the trial period;

18. Excessive consumption of tea, coffee or caffeinated beverages (defined as: at least
8 cups per day, 1 cup =250 ml) in the 3 months prior to screening, or intake of
caffeine or xanthine-rich foods or beverages (such as coffee, tea, chocolate, cola,
etc.) within 48 hours prior to the first dose;

19. Consumed food, juice or drink containing grapefruit, lime, cinchona peel or quinine
within 48 hours before screening and until check-in;

20. Positive or above the upper limit of the reference range for four hemodialysis
tests, including hepatitis B surface antigen (HBsAg), hepatitis C (HCV) antibodies,
human immunodeficiency virus (HIV) antibodies or treponema pallidum antibodies;

21. Other circumstances in which the investigator (or his designee) deems it
inappropriate to participate in the study.